Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Celera Acquires Axys Pharmaceuticals in Push to Accelerate Drug Discovery Capabilities

NEW YORK, June 13 - Celera Genomics announced its intention Wednesday to acquire Axys Pharmaceuticals in a stock transaction valued at $173.4 million, making good on its promise to purchase a company with chemistry and drug design capabilities.

In the stock-for-stock transaction, Celera will pay Axys shareholders the equivalent of $4.65 per Axys share, representing a 35 percent premium based on Axys' Tuesday closing price of $3.45 a share. Axys reported 37.3 million shares outstanding in its first quarter earnings.

Celera, of Rockville, Md., said it hopes to use Axys' chemical libraries of small molecules and its experience in structural and medicinal chemistry to identify potential drugs for protein targets that Celera identifies through its proteomics program.

"We believe Axys has the technical capabilities, infrastructure, and most importantly the people to take us forward," said Peter Chambre, Celera's chief operating officer, in a conference call to discuss the transaction.

As part of the new company, Axys' senior management will take positions within Celera, and Axys' team of 55 chemists and biologists will work together with Celera's scientific team. Michael Venuti, Axys' vice president for research and development, will report to Craig Venter, Celera's president, and Paul Hastings, Axys' CEO, will report to Chambre.

Chambre said that Celera would allow Axys, of South San Francisco, to continue in its current collaborations with Merck to develop lead drug compounds for osteoporosis, and with Aventis to identify lead compounds for inflammatory and autoimmune diseases. 

In addition to its collaborations, Axys also has its own drug development efforts in oncology, but Venter made clear that Celera did not buy Axys for the drugs currently in its pipeline, but instead for its capabilities in biology and chemistry.

"We did not do this based on the pipeline that has existed or does exist," he said. "But we're not going to ignore it either."

Hastings added that Axys would try to find partners to further develop the drugs currently in its pipeline, and would focus primarily on finding drug candidates for Celera's targets.

Venter said that Celera has targeted four key disease areas in its drug discovery efforts, including colon, pancreas, lung, and breast cancer. He did not comment specifically on what disease or areas or class of drug targets Axys' team of chemists would tackle initially. 

Axys is currently building a new 43,000 square foot medicinal chemistry facility in South San Francisco that will house up to 80 chemists, Hastings said. In addition, Axys has access as a customer to the combinatorial chemistry libraries of its former subsidiary Axys Advanced Technologies, now a part of San Diego-based Discovery Partners.

Axys, however, won't solve all of Celera's needs, said Tony White, CEO of Applera, Celera's parent corporation. The company still needs to build or acquire capabilities in target validation, he said, "because we don't think we can achieve all that we need in this area."

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.